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Biotechnology derived medicinal products are presently the best characterized biologicals with
considerable production and clinical experience, and have revolutionized the treatment of some of the
most difﬁcult-to-treat diseases, prolonging and improving the quality of life and patient care. They are
also currently one of the fastest growing segments of the pharmaceutical industry market. The critical
challenge that the biopharmaceutical industry is facing is the expiry of patents for the ﬁrst generation of
biopharmaceuticals, mainly recombinant DNA derived products, such as interferons, growth hormone
and erythropoetin. The question that immediately arose was how should such copies of the originator
products be licensed, bearing in mind that they are highly complex biological molecules produced by
equally complex biological production processes with their inherent problem of biological variability.
Copying biologicals is much more complex than copying small molecules and the critical issue was how
to handle the licensing of products if relying in part on data from an innovator product. Since 2004 there
has been considerable international consultation on how to deal with biosimilars and biological copy
products. This has led to a better understanding of the challenges in the regulatory evaluation of the
quality, safety and efﬁcacy of “biosimilars”, to the exchange of information between regulators, as well as
to the identiﬁcation of key issues. The aim of this article is to provide a brief overview of the scientiﬁc and
regulatory challenges faced in developing and evaluating similar biotherapeutic products for global use.
It is intended as an introduction to the series of articles in this special issue of Biologicals devoted to
similar biotherepeutic products.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
In the 1980s novel biological medicines produced by recombi-
nant DNA technology appeared on the horizon. The bio-
pharmaceutical industry has expanded dramatically over the last
30 years since the ﬁrst successes of recombinant DNA technology.
Over the last ﬁve years, there has been a considerable increase in
the range of biotech products with a corresponding increase in
their use in multiple therapy areas. At a very early stage, the EMA
and the US FDA developed guidelines and points to consider
respectively for the development and evaluation of these new
products. Such guidance set the scene for regulatory expectations
both for clinical trials and marketing authorization. At the global
level, WHO produced a series of guidance documents on the
quality, safety and efﬁcacy of products prepared by recombinant
DNA technology, including speciﬁc guidance for certain types of: þ41 22 791 4971.
), elwyn.grifﬁths@hc-sc.gc.ca
ll rights reserved. The World Healthproducts such as interferons and monoclonal antibodies [1e4].
There was no question that these products should be considered as
biologicals even though they were usually much better character-
ized than their natural equivalents. The guidance put in place at
that time built on the long experience of testing and licensing
biologicals and emphasised rigorous characterization of the
production system and product, as well as the need for in process
control procedures to ensure consistency of production. These
concepts have served us well over the years and rDNA derived
medicines became the safe and effective therapies which play
a major role in today’s medical practice. Indeed, biotechnology
derived medicinal products are presently the best characterized
biologicals with considerable accumulated experience with their
production and clinical use, revolutionizing the treatment of some
of the most difﬁcult-to-treat diseases and helping to prolong and
improve quality of life and patient care.
Due to the biological nature of these products, they have been
named differently in different jurisdictions. Most frequently used
terms include but are not limited to the following: bio-
pharmaceuticals, biomedicines, biotherapeutics or biotechnologyOrganization has granted the Publisher permission for the reproduction of this article.
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under the general biologicals umbrella while in others they are
regulated as pharmaceuticals. As a group, they represent one of the
most dynamic and promising segments of the pharmaceutical
industry, having enjoyed a rapid expansion over the past few years
with compounded growth rates exceeding double-digit ﬁgures.
This is largely outpacing the overall performance of the pharma-
ceutical market. Currently, it represents the highest growth rate
sector for the pharmaceutical industry. Developments in protein
expression systems and cell culture technologies, along with major
advances in analytical characterization capabilities, are at the core
of the biopharmaceutical industry’s rapid growth. As an illustra-
tion, global sales of biopharmaceuticals amounted to $47.58 billion
in 2003, increased to $85.94 billion by 2007. According to IMS data,
sales of biopharmaceuticals represented 9.6% of the global phar-
maceutical sales in 2003. By 2007 this has increased to 12.1% of the
global pharmaceutical sales [5]. Although the world biotechnology
market has more than doubled in the last ﬁve years, innovative
biotechnology derived medicines are expensive and there has
always been a problem of access for many patients around the
world, even in developed countries. In some instances the use of
biotechnology products is a major drain on publicly funded health
programmes. As the patents and data protection measures expired
or neared expiration considerable interest turned to producing
copies of these products as a means of not only obtaining a share in
this lucrative market but also, from a social perspective, of making
more affordable medicines thus increasing global access to much
needed biological medicines. Even a modest reduction in costs
could result in signiﬁcant savings to a health care system.
2. Appropriate regulatory oversight of biological copy
products
The question that immediately arose was how should such copy
products be licensed, bearing in mind that they are highly complex
biological molecules produced by equally complex biological
production processes with their inherent problem of biological
variability. Could these copies be considered as generics and be
subjected to minimum regulatory oversight, or did their authori-
zation still require full scale clinical evaluation even though there
was a considerable body of clinical experience with the use of the
innovator products? The latter approach would likely lead to new
products whichwould not be signiﬁcantly more affordable than the
originators. Maybe new regulatory pathways were needed where
there was reliance, even in part, on clinical experience with inno-
vator products. This possibility led to much manufacturer and
regulatory interest worldwide. The key questionwas how to handle
the licensing of products if relying in part on data from an innovator
product. Copying biologicals would be much more complex than
copying small molecules. Many biologicals are made up not only of
the amino acid sequence in the protein chain but also of various
polysaccharides which are added onto the peptide backbone during
post-translational modiﬁcations. Small changes, such as deamida-
tion, oxidation or N- and C-terminal differences, can also occur in
the peptide backbone. Details of this vary depending on the
production process and may or may not affect overall clinical
performance. Separation and analytical technologies have
improved tremendously since the early days of biotechnology and
many of these biological macromolecules can now be characterized
in exquisite detail using a range of analytical techniques. Never-
theless, it is still not possible to fully predict biological properties
and clinical performance from physicochemical characteristics
alone. Consistency of production is therefore critical and it is
known that slight production changes can occasionally lead to
major adverse clinical effects, such as immunogenicity with serioussafety implications. Therefore, some clinical data will certainly be
required for a new copy product, but how much?
In practice, dealing with these copy molecules has involved not
only scientiﬁc considerations, but also those related to intellectual
property and legal aspects of the regulatory frameworks of
different jurisdictions. In addition, naming copy products, and
a need to distinguish originators from subsequently developed
copy products also on the market, has been much debated but has
huge practical implications. Interchangeability and substitutability
are two key issues regarding the use of these copy products at the
global level and opinions on this are sharply divided. However, it is
clear that decisions on their actual use can only be taken at the
national or possibly regional level.
3. Biosimilars versus copy biologicals: key events in the past
decade
The EMAwas the ﬁrst regulatory authority to tackle this problem
when in 2004 it developed the concept of similar biological
medicinal products, popularly shortened to biosimilars, and in 2005
developed a regulatory framework and guidelines for dealing with
them. This involves a comparability exercise which relies on a head
to head demonstration of “similarity” of the new product’s charac-
teristics (physicochemical and biological activity) to a chosen
licensed reference biological product (RBP)which in turn, providing
similarity is shown, can lead to a reduced non-clinical and clinical
data package. This will still include some head to head clinical
comparison with the same reference product, especially with
regards to immunogenicity. Subsequently, the EMA developed
product speciﬁc guidelines (http://www.ema.europa.eu/) andhas to
date licensed fourteen biosimilar products.
Since 2004 there has been considerable international consul-
tation on how to deal with biosimilars and biological copy products.
This has led to a better understanding of the challenges in the
regulatory evaluation of the quality, safety and efﬁcacy of “bio-
similars”, to the exchange of information between regulators, as
well as to the identiﬁcation of key issues and gaps. It became clear
that there was, globally, a wide range of regulatory preparedness
and experience not only in dealing with biosimilars, but also in
dealing with biotechnology products in general, and that there was
a need for regulatory global road map. At the International
Conference of Drug Regulatory Authorities (ICDRA), Seoul, 2006,
WHO was requested to develop a global regulatory consensus and
guidance on this evolving topic and the following years have seen
a number of WHO consultations on nomenclature (INNs) and on
regulatory evaluation of “biosimilars”, involving regulators and
manufacturers. An important point of agreement globally was that
biosimilars do not meet criteria for true generics and should not be
regulated under generic (small molecule) drugs regulations. There
was also agreement on the possibility of licensing a new biological
medicinal product on basis of its “similarity” with a well estab-
lished licensed originator product. This would involve extensive
product characterization and an abridged non-clinical and clinical
data package would be appropriate.
Following the recommendation from the ICDRA in 2006, WHO
convened an informal consultation on the regulatory evaluation of
therapeutic biological medicines to identify the current status and
regulatory challenges of similar biotherapeutic products (SBPs) in
April 2007 in Geneva [6]. At this consultation, it was agreed that
WHO should develop guidelines on the regulation of such products
and a WHO drafting group was established. Further discussion at
a consultation organized by the WHO and the Korea Food and Drug
Administration in Seoul, May 2008, led to the production of
document WHO/BS/08.2101 which was submitted to the WHO
Expert Committee on Biological Standardization (ECBS) in October
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package would be suitable for licensing certain products. However,
further clariﬁcation of the criteria for reducing clinical data was
requested and the safety assessment of SBPs was identiﬁed as
a critical component for licensing and post-marketing surveillance.
Following revision undertaken by the WHO drafting group in
Tokyo, Japan, in February 2009, a revised draft was made available
for broad public consultation as well as review at a consultation
held in Ottawa, Canada, organized by WHO and Health Canada.
More than 30 participants from Canada, USA, EU, Switzerland,
Cuba, China, Republic of Korea, India, Malaysia, Brazil, South Africa,
Iran and Thailand reviewed their experience in setting national
requirements for SBPs on the basis of the draftWHOGuidelines and
made a number of proposals for further improvement. Following
this extensive international consultation over a number of years,
the WHO guidelines were ﬁnally adopted by the ECBS in October
2009. The Committee recommended that issues subject to partic-
ular national situations be excluded from the Guidelines. These
include but are not limited to: 1) intellectual property issues; 2)
interchangeability and substitutability of SBP with RBP and 3)
labeling and prescribing information. The ECBS also recommended
that WHO play an active role in facilitating the implementation of
the principles outlined in the document into regulatory and
manufacturers’ practice worldwide.
TheWHOGuidelines on the Evaluation of Similar Biotherapeutic
Products, published in 2010, rely on a head to head demonstration
of “similarity” of new product characteristics (physicochemical/
biological activity) to a chosen licensed reference product to justify
a reduced non-clinical and clinical data package [7]. This head to
head comparability exercise, with the same reference product
throughout, involves not only quality but also non-clinical and
clinical aspects and the Guidelines emphasize the need to employ
testing strategies that are sensitive enough to detect any relevant
differences between the new product and the reference biological
product. In particular, the Guidelines point out that the clinical
studies should be designed speciﬁcally to demonstrate comparable
safety and efﬁcacy between the products using well established
clinical models and, preferably, equivalence rather than non-
inferiority designs, and not just to establish the overall safety and
efﬁcacy proﬁle of the new product. Such targeted studies would be
expected to be smaller than normal clinical trials. Also, if similarity
in physicochemical and biological properties has been demon-
strated, as well as in efﬁcacy and safety for a particular indication,
extrapolation of these data to other indications of the reference
product not studied in independent clinical studies with the similar
biotherapeutic product may be possible provided certain condi-
tions are met.
The WHO Guidelines are intended to provide a globally
acceptable set of basic principles regarding the evaluation of bio-
similars but it is recognized that theywill not by themselves resolve
all issues. Several countries have developed their own guidelines
(see this volume of Biologicals) but there are some differences in
details between jurisdictions regarding, for example, the choice of
reference biological product (RBP) or the extent of extrapolation of
indications allowed from an abridged set of clinical studies. The
acceptability of the RBP which is not licensed by the NRA but is
licensed in another country (so called “foreign RBP”) is a reasonable
approach for the NRAs of countries with a small market for RBPs.
The beneﬁt of using nationally licensed RBPs is that much of the
performance and other data will be readily available to the NRA. On
the other hand, the use of a foreign RBP requires well deﬁned
criteria for its acceptability and for the reliability of the NRA where
the product is licensed. Some countries have established a list of
recognized NRAs as a basis for considering products licensed by
these authorities as potential candidates for RBPs. This is a sort ofunilateral recognition that may work well between and among
certain countries.
There seems also to be some differences in the interpretation of
an appropriate comparability exercise. In some countries, compa-
rability in the quality aspects has been interpreted to mean
a comparison to a national standard. Furthermore, there is less
agreement amongst jurisdictions worldwide, especially in devel-
oping countries, as to whether this type of regulatory pathway,
involving head to head comparison of quality, non-clinical and
clinical attributes of a new product with an authorized and well
used original, should always be used or indeed can be used under
some circumstances. A number of reports from developing coun-
tries have revealed a problem in obtaining sufﬁcient quantities of
the originator product for the purpose of using it as an RBP in
comparability studies. The price of originator products may be one
of the limiting factors whilst the political situation in other coun-
tries creates a barrier to trade resulting in limiting access to these
products. Manufacturers from developing countries have also
identiﬁed access to information generated on an RBP as a difﬁcult
issue in conducting the comparability exercise. Some jurisdictions
therefore question the need for the direct head to head quality
comparability studies and favour regulatory pathways based more
on a stand alone approach. Nevertheless, at the WHO Consultation
in Seoul in 2010, it was reafﬁrmed that only medicinal products
authorized on the basis of a full comparability package involving
quality, non-clinical and clinical aspects, should be called bio-
similars (or Similar Biotherapeutic Products, Subsequent Entry
Biologics, Follow On Biologics). It has been suggested that copy
products appropriately licensed by other pathways might be called
“non-innovator biological products”.
4. Way forward: global consensus and national solutions
Although the debate on how best to license copy biological
products using reduced non-clinical and clinical data packages
continues, there is increasing alignment between jurisdictions.
However, there will be inevitably some differences due to national
regulations and needs. There will also be differences in the scope of
which type of products are included under the umbrella of bio-
similars. Biologicals are mostly protein based although poly-
saccharide and DNA molecules may be considered for SBP status in
some cases. Vaccines are not included in the WHO Guidelines since
there are already WHO recommendations or guidelines dealing
with this issue. When a new vaccine comes to licensing following
a product already licensed on the basis of large clinical protection
studies for the same indication, it is accepted that in some cases
smaller targeted comparative immunogenicity studies maybe
appropriate as a measure of efﬁcacy. Furthermore, the guiding
principles in the WHO Guidelines on SBPs do not provide a sufﬁ-
cient level of detail regarding the evaluation of the quality, safety
and efﬁcacy of vaccines. Therefore, WHO recommendations on the
quality, safety and efﬁcacy of speciﬁc vaccines will continue to be
provided in vaccine speciﬁc documents (http://www.who.int/
biologicals/en).
Since the publication of the WHO Guidelines, several activities
at the global and regional level have been conducted by WHO. An
issue of critical importance for the appropriate evaluation of copy
and similar biological products is the expertise of the regulators
responsible for the licensing of biotherapeutic products. Much
investment in the development of biosimilar and copy products is
now going on in many countries, including those with emerging
economies and it is recognized that the regulatory agencies of many
of these countries need also to be strengthened with respect to
their regulatory oversight of biotechnology products as well as
biosimilars. In 2010, the ﬁrst WHO implementation workshop was
I. Knezevic, E. Grifﬁths / Biologicals 39 (2011) 252e255 255held and a survey in 13 countries was conducted. Signiﬁcant
improvement in the understanding of the need for clinical trials
and of the importance of having an appropriate design of compa-
rability studies, and of the clinical part in particular, were noted.
Nevertheless, there is much to do in capacity building of both
manufacturers and regulatory authorities globally where technical
expertise is limited. Regional initiatives are already well underway
in some quarters (PAHO through PANDRH) but needs may differ
from region to region. Work sharing agreements may be a way
forward in some situations. An example of such international
cooperation is the joint involvement of both the manufacturers and
regulatory agencies of Brazil and Cuba in the developments of these
products. The achievements in this area were presented to the
ICDRA in Singapore in December 2010. The meeting noted that
a serious problem exists in some countries where copy biological
products have already been licensed on very minimal data, some-
times as simple generics, and that these countries may need advice
as to how best to deal with and regulate the situation. It is expected
that WHO will assist such countries to establish appropriate
approaches for evaluating these products properly or for phasing
them out in a reasonable period of time.
WHO’s role in building the technical expertise in NRAs world-
wide is recognized as an important contribution towards better
regulation of biotherapeutics as awhole. One of the speciﬁc tasks in
coming years will be the provision of appropriate scientiﬁc prin-
ciples for the evaluation of biotherapeutics as stand alone products.
This will involve updating existing WHO documents [1e4] to
include the numerous issues that have emerged over time. It is
expected that implementation workshops will continue and be
devoted to speciﬁc aspects, such as the comparability exercise in
terms of quality parameters. Increasing knowledge in assessing
SBPs, exchange of information among regulators, regular update
regarding the licensure of SBPs and key issues that have been
raised by evaluators and the development of training curricula are
some of the activities that could be organized through WHO
collaborating centers. In spite of the initiatives at the global level, it
is expected that national solutions will make a real difference in
terms of the use of SBPs. The involvement of all relevant parties at
the country level is a key prerequisite for the success in increasing
patients’ access to the biotherapeutic products that are most
needed. In addition to the regulators and manufacturers, publichealth authorities, health care providers, general practitioners,
pharmacists and patients’ organizations all need to be consulted
during the decisionmaking process regarding the actual use of SBPs
at the country and/or provincial level. There are great expectations
and opportunities in this ﬁeld but the level of complexity of bio-
therapeutic products still demand a degree of respect and caution,
as well as sound regulatory oversight.
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